|
Name |
Rhinomilisin A
|
Molecular Formula | C30H41ClO10 | |
IUPAC Name* |
(5aR,6S,9R,9aR)-9-[[(5aR,6S,9R,9aR)-9-(chloromethyl)-9-hydroxy-1-oxo-6-propan-2-yl-3,5a,6,7,8,9a-hexahydro-2-benzoxepine-4-carbonyl]oxymethyl]-9-hydroxy-1-oxo-6-propan-2-yl-3,5a,6,7,8,9a-hexahydro-2-benzoxepine-4-carboxylic acid
|
|
SMILES |
CC(C)[C@@H]1CC[C@@]([C@H]2[C@H]1C=C(COC2=O)C(=O)O)(COC(=O)C3=C[C@H]4[C@@H](CC[C@@]([C@@H]4C(=O)OC3)(CCl)O)C(C)C)O
|
|
InChI |
InChI=1S/C30H41ClO10/c1-15(2)19-5-7-29(37,13-31)23-22(19)10-18(12-40-27(23)35)26(34)41-14-30(38)8-6-20(16(3)4)21-9-17(25(32)33)11-39-28(36)24(21)30/h9-10,15-16,19-24,37-38H,5-8,11-14H2,1-4H3,(H,32,33)/t19-,20-,21-,22-,23-,24-,29-,30-/m0/s1
|
|
InChIKey |
FIEQQNHDRLOILS-TYKFYTCVSA-N
|
|
Synonyms |
Rhinomilisin A
|
|
CAS | NA | |
PubChem CID | 145720940 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 597.1 | ALogp: | 2.9 |
HBD: | 3 | HBA: | 10 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 157.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 41 | QED Weighted: | 0.225 |
Caco-2 Permeability: | -5.662 | MDCK Permeability: | 0.00001210 |
Pgp-inhibitor: | 0.018 | Pgp-substrate: | 0.012 |
Human Intestinal Absorption (HIA): | 0.074 | 20% Bioavailability (F20%): | 0.984 |
30% Bioavailability (F30%): | 0.87 |
Blood-Brain-Barrier Penetration (BBB): | 0.818 | Plasma Protein Binding (PPB): | 83.33% |
Volume Distribution (VD): | 0.68 | Fu: | 7.42% |
CYP1A2-inhibitor: | 0.015 | CYP1A2-substrate: | 0.123 |
CYP2C19-inhibitor: | 0.027 | CYP2C19-substrate: | 0.173 |
CYP2C9-inhibitor: | 0.08 | CYP2C9-substrate: | 0.085 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.086 |
CYP3A4-inhibitor: | 0.285 | CYP3A4-substrate: | 0.255 |
Clearance (CL): | 8.82 | Half-life (T1/2): | 0.09 |
hERG Blockers: | 0.093 | Human Hepatotoxicity (H-HT): | 0.297 |
Drug-inuced Liver Injury (DILI): | 0.867 | AMES Toxicity: | 0.197 |
Rat Oral Acute Toxicity: | 0.663 | Maximum Recommended Daily Dose: | 0.932 |
Skin Sensitization: | 0.259 | Carcinogencity: | 0.408 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.032 |
Respiratory Toxicity: | 0.404 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004012 | 0.627 | D0X4RS | 0.250 | ||||
ENC003999 | 0.562 | D0V2JK | 0.242 | ||||
ENC004011 | 0.476 | D06AEO | 0.230 | ||||
ENC004919 | 0.423 | D0K7HU | 0.229 | ||||
ENC004063 | 0.369 | D05RXI | 0.229 | ||||
ENC005090 | 0.352 | D02CNR | 0.229 | ||||
ENC005682 | 0.319 | D04GJN | 0.226 | ||||
ENC005681 | 0.283 | D0IX6I | 0.221 | ||||
ENC004921 | 0.275 | D0X6GN | 0.221 | ||||
ENC004003 | 0.273 | D01CKY | 0.216 |